Mellett J. Paul's most recent trade in Enanta Pharmaceuticals Inc was a trade of 7,500 Common Stock done . Disclosure was reported to the exchange on Feb. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Chief Fin. & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 7,500 | 99,210 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Chief Fin. & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.59 per share. | 12 Feb 2025 | 3,326 | 95,884 (0%) | 0% | 5.6 | 18,592 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Chief Fin. & Admin Officer | Sale of securities on an exchange or to another person at price $ 8.06 per share. | 06 Dec 2024 | 2,591 | 91,710 (0%) | 0% | 8.1 | 20,883 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Chief Fin. & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.60 per share. | 01 Dec 2024 | 1,595 | 94,301 (0%) | 0% | 8.6 | 13,717 | Common Stock |
| Enanta Pharmaceuticals Inc | Mellett J. Paul | Chief Fin. & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Nov 2024 | 81,000 | 81,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | J. Mellett Paul | Chief Fin. & Admin Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2024 | 3,320 | 96,869 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Chief Fin. & Admin Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.41 per share. | 12 Feb 2024 | 973 | 95,896 (0%) | 0% | 12.4 | 12,075 | Common Stock |
| Enanta Pharmaceuticals Inc | J. Paul Mellett | Sr. VP, Finance & Admin. & CFO | Sale of securities on an exchange or to another person at price $ 9.63 per share. | 05 Dec 2023 | 2,412 | 93,549 (0%) | 0% | 9.6 | 23,228 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Sr. VP, Finance & Admin. & CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.49 per share. | 01 Dec 2023 | 1,595 | 95,961 (0%) | 0% | 9.5 | 15,137 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Sr. VP, Finance & Admin. & CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Nov 2023 | 83,000 | 83,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.00 per share. | 15 Mar 2023 | 10,440 | 107,996 (0%) | 0% | 14 | 146,160 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Mar 2023 | 10,440 | 0 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 44.43 per share. | 15 Mar 2023 | 10,340 | 97,556 (0%) | 0% | 44.4 | 459,406 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 43.96 per share. | 15 Mar 2023 | 100 | 107,896 (0%) | 0% | 44.0 | 4,396 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 11,747 | 104,460 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 9,250 | 92,713 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 52.77 per share. | 13 Feb 2023 | 6,904 | 97,556 (0%) | 0% | 52.8 | 364,324 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 53.64 per share. | 09 Feb 2023 | 4,200 | 84,263 (0%) | 0% | 53.6 | 225,288 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 54.41 per share. | 09 Feb 2023 | 800 | 83,463 (0%) | 0% | 54.4 | 43,528 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jan 2023 | 2,812 | 0 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.18 per share. | 09 Jan 2023 | 2,812 | 88,463 (0%) | 0% | 14.2 | 39,874 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2022 | 4,148 | 0 | - | - | Stock Option (Right to Buy) | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.18 per share. | 19 Dec 2022 | 4,148 | 85,651 (0%) | 0% | 14.2 | 58,819 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 44.33 per share. | 01 Dec 2022 | 1,055 | 81,503 (0%) | 0% | 44.3 | 46,768 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 45,000 | 45,000 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Nov 2022 | 21,000 | 82,558 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Jun 2022 | 3,480 | 0 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 11.77 per share. | 17 Jun 2022 | 3,480 | 61,558 (0%) | 0% | 11.8 | 40,960 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 2,419 | 59,036 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 62.49 per share. | 14 Feb 2022 | 958 | 58,078 (0%) | 0% | 62.5 | 59,865 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2022 | 615 | 56,617 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 28,400 | 28,400 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2021 | 6,800 | 56,559 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Sale of securities on an exchange or to another person at price $ 45.58 per share. | 08 Jan 2021 | 6,000 | 61,759 (0%) | 0% | 45.6 | 273,463 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 2,625 | 56,529 (0%) | 0% | - | Common Stock | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2020 | 2,625 | 0 | - | - | Restricted Stock Units | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.52 per share. | 15 Dec 2020 | 770 | 55,759 (0%) | 0% | 42.5 | 32,740 | Common Stock |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 30,800 | 30,800 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2020 | 7,600 | 53,904 (0%) | 0% | 0 | Common Stock | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2020 | 3,480 | 0 | - | - | Stock Option (right to buy) | |
| Enanta Pharmaceuticals Inc | Paul J. Mellett | Treasurer and CFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.54 per share. | 11 Nov 2020 | 3,480 | 46,304 (0%) | 0% | 2.5 | 8,849 | Common Stock |